X0508 4 2023-12-29 0001636282 Spyre Therapeutics, Inc. SYRE 0001802528 Fairmount Funds Management LLC 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001686157 Fairmount Healthcare Fund L.P. 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001769651 Fairmount Healthcare Fund II L.P. 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001982220 Fairmount Healthcare Co-Invest L.P. 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001830177 Kiselak Tomas 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false 0001663607 Harwin Peter Evan 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false true false true Common Stock 2023-12-29 4 J false 3435480 0.00 D 0 I By Fairmount Healthcare Co-Invest L.P. Common Stock 2023-12-29 4 J false 406038 0.00 A 406038 I By Tomas Kiselak Common Stock 2023-12-29 4 J false 406038 0.00 A 406038 I By Peter Harwin Common Stock 378421 I By Fairmount Healthcare Fund II L.P. Series A Preferred Stock Common Stock 17481480 437037 I By Fairmount Healthcare Fund II L.P. Series B Preferred Stock Common Stock 666680 16667 I By Fairmount Healthcare Fund II L.P. Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. On December 29, 2023, the shares of Common Stock and Series A non-voting convertible preferred stock (the "Series A Preferred Stock") held by Fund I were transferred to Fund II. Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC. /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 2023-12-29 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund L.P. 2023-12-29 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P. 2023-12-29 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest L.P. 2023-12-29 /s/ Tomas Kiselak 2023-12-29 /s/ Peter Harwin 2023-12-29